Vemurafenib

Generic Name
Vemurafenib
Brand Names
Zelboraf
Drug Type
Small Molecule
Chemical Formula
C23H18ClF2N3O3S
CAS Number
918504-65-1
Unique Ingredient Identifier
207SMY3FQT
Background

Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collab...

Indication

Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.
...

Associated Conditions
Metastatic Melanoma, Refractory Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Refractory Erdheim-Chester disease
Associated Therapies
-
Clinical Trials
Related News

A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Phase 2
Completed
Conditions
Metastatic Melanoma
Interventions
Drug: Cobimetinib
Drug: Vemurafenib
First Posted Date
2016-05-11
Last Posted Date
2019-08-28
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
40
Registration Number
NCT02768207
Locations
🇧🇪

UZ Brussel, Brussel, Belgium

🇧🇪

UZ Antwerpen, Edegem, Belgium

🇧🇪

Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium

and more 11 locations

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1
Active, not recruiting
Conditions
Melanoma
Skin Cancer
Interventions
Drug: XL888
Drug: Vemurafenib
Drug: Cobimetinib
First Posted Date
2016-03-29
Last Posted Date
2024-11-20
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
26
Registration Number
NCT02721459
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

First Posted Date
2015-12-23
Last Posted Date
2020-03-19
Lead Sponsor
Samsung Medical Center
Target Recruit Count
90
Registration Number
NCT02638428
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

First Posted Date
2015-11-18
Last Posted Date
2020-02-12
Lead Sponsor
Genentech, Inc.
Target Recruit Count
32
Registration Number
NCT02608034
Locations
🇮🇱

Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, Israel

🇰🇷

Samsung Medical Center; Gastroenterology, Seoul, Korea, Republic of

🇷🇺

FSBSI "N. N. Blokhin Russian Cancer Research Center", Moscow, Russian Federation

and more 8 locations

Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

Phase 1
Completed
Conditions
Thyroid Cancer
Interventions
Biological: KTN3379
Drug: vemurafenib
First Posted Date
2015-05-28
Last Posted Date
2017-09-05
Lead Sponsor
Celldex Therapeutics
Target Recruit Count
7
Registration Number
NCT02456701
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies

First Posted Date
2015-05-12
Last Posted Date
2017-11-14
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
6
Registration Number
NCT02441465
Locations
🇭🇺

Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Phase 3
Withdrawn
Conditions
Melanoma
Interventions
Drug: Cobimetinib
Drug: Vemurafenib
First Posted Date
2015-04-28
Last Posted Date
2016-11-15
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Registration Number
NCT02427893
Locations
🇺🇸

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Vemurafenib and TIL Therapy for Metastatic Melanoma

First Posted Date
2015-02-03
Last Posted Date
2020-03-23
Lead Sponsor
Inge Marie Svane
Target Recruit Count
13
Registration Number
NCT02354690
Locations
🇩🇰

Center for Cancer Immune Therapy, Dept. of Haematology/Oncology, Copenhagen, Herlev, Denmark

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

First Posted Date
2014-12-11
Last Posted Date
2023-12-04
Lead Sponsor
University College, London
Target Recruit Count
50
Registration Number
NCT02314481
Locations
🇬🇧

Univeristy College London Hospital, London, United Kingdom

Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Phase 2
Active, not recruiting
Conditions
Solid Tumors
Hematologic Cancers
Metastatic Cancers
Interventions
Drug: Vemurafenib
First Posted Date
2014-12-02
Last Posted Date
2024-06-07
Lead Sponsor
UNICANCER
Target Recruit Count
216
Registration Number
NCT02304809
Locations
🇫🇷

Tredaniel, Paris, France

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy